密苏里大学医学院教授 Ai-Ling Lin 领导的一项试点研究发现,抗衰老药物雷帕霉素(rapamycin)可能有助于改善易患阿尔茨海默病人群的脑部血液流动 1。该研究针对45至65岁的健康成年人进行,参与者包括携带和不携带高风险 APOE4 基因变异的人群 1。所有受试者在四周内每日接受低剂量雷帕霉素治疗,结果显示携带 APOE4 基因的参与者脑部血流量显著改善,而未携带该基因者未观察到同样益处 1。这一发现具有重要意义,因为脑血流下降通常发生在阿尔茨海默病临床症状显现之前数年,提示在记忆丧失开始前通过干预延缓疾病进程的可能性 1。
研究进一步指出,性别因素在治疗效果中扮演关键角色,其中携带 APOE4 基因的女性表现出最大的脑部血流量改善 1。鉴于全球约三分之二的阿尔茨海默病患者为女性,这一结果凸显了针对特定人群早期预防策略的价值 1。相关论文《EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial》已发表于《Journal of Cerebral Blood Flow & Metabolism》 1。
Researchers at the University of Missouri have found that rapamycin, an anti-aging drug, may help protect the brains of individuals prone to Alzheimer's disease. 1 In a pilot study involving healthy adults aged 45 to 65, participants took low doses of rapamycin daily for four weeks. 1 The research was led by Professor Ai-Ling Lin at the University of Missouri School of Medicine. 1
The study included both carriers and non-carriers of the high-risk APOE4 gene variant. 1 Results showed that cerebral blood flow improved significantly in participants carrying the APOE4 gene, while no such benefits were observed in those without the variant. 1 Among the APOE4 carriers, women exhibited the most substantial improvement in brain blood flow. 1 This finding is notable given that approximately two-thirds of people with Alzheimer's disease worldwide are female. 1
Since decreased brain blood flow typically occurs years before Alzheimer's symptoms manifest, these results offer new hope for preventing or delaying the disease before memory loss begins. 1 The study was published in the Journal of Cerebral Blood Flow & Metabolism under the title "EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial." 1 The paper is accessible via DOI 10.1177/0271678X261490342. 1
评论
还没有评论,欢迎留下第一条。